Viral Genome Sequencing Global Market Report 2026

The viral genome sequencing market size has grown rapidly in recent years. It will grow from $6.71 billion in 2025 to $7.72 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to rising prevalence of viral outbreaks, adoption of next-generation sequencing, growth of clinical diagnostics, government funding for research, demand for epidemiological studies.

The viral genome sequencing market size is expected to see rapid growth in the next few years. It will grow to $13.57 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to ai-driven genome analysis, expansion of vaccine development programs, adoption of portable sequencing technologies, integration with predictive bioinformatics, increasing focus on real-time pathogen monitoring. Major trends in the forecast period include high-throughput viral genome sequencing, portable sequencing devices, integration with bioinformatics platforms, automated sample processing, real-time mutation tracking.

The increasing prevalence of infectious diseases is expected to drive the growth of the viral genome sequencing market. Infectious diseases, caused by pathogenic microorganisms, are rising globally due to factors such as international travel, urbanization, and rapid cross-border transmission of pathogens. This growing disease burden has prompted governments and healthcare systems to strengthen genomic surveillance and outbreak response capabilities. Viral genome sequencing is essential for infectious disease management by enabling rapid identification of viral strains, monitoring mutations, tracking transmission pathways, and supporting targeted public health interventions. For example, in February 2026, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, influenza caused approximately 290,000-450,000 hospitalizations and 34,000-53,000 deaths annually in the United States, while RSV accounted for an estimated 190,000-350,000 hospitalizations and 10,000-23,000 deaths. Therefore, the increasing prevalence of infectious diseases is propelling the viral genome sequencing market.

Major companies in the viral genome sequencing market are emphasizing progress in long read sequencing technologies such as benchtop long read sequencing platforms to strengthen their competitive position. A benchtop long read sequencing platform is a compact laboratory system built to produce highly accurate and extended nucleotide reads from viral genomes. This capability allows detailed identification of structural variants, better genome assembly, and quicker processing for pathogen analysis. It also improves surveillance capacity, assists outbreak response efforts, and increases research accuracy, although it requires substantial capital investment and sophisticated data analysis infrastructure for large scale use. For example, in November 2024, Pacific Biosciences, a biotechnology company based in the United States, launched the Revio benchtop HiFi sequencing platform. The system provides high fidelity long reads, higher throughput than earlier platforms, and scalable configuration suitable for both clinical and research laboratories, supporting more effective tracking of viral mutations and more complete genome sequencing in the viral genome sequencing market.

In February 2025, Deerfield Management Company, a US-based investment management firm specializing in healthcare innovation, acquired Singular Genomics Systems for an undisclosed amount. Through this acquisition, Deerfield aims to provide Singular Genomics with enhanced strategic flexibility to advance its next-generation sequencing and spatial multiomics technologies for researchers and clinicians. Singular Genomics is a US-based provider of NGS platforms, including the G4 sequencing platform for genomic sequencing and the developing G4x spatial sequencer for multiomics applications.

Major companies operating in the viral genome sequencing market are F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio‑Rad Laboratories Inc., QIAGEN N.V., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Novogene Co. Ltd., Takara Bio Inc., Twist Bioscience Corporation, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Genewiz, Macrogen Inc., MedGenome Labs Ltd., Eurofins Scientific SE, CD Genomics, BGI Genomics Co. Ltd.

North America was the largest region in the viral genome sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral genome sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral genome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral genome sequencing market includes revenues earned by providing services such as whole viral genome sequencing, targeted amplicon sequencing, metagenomic sequencing for pathogen discovery, viral variant analysis and mutation profiling, and bioinformatics data interpretation and phylogenetic analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral genome sequencing is a laboratory method for determining the complete nucleotide sequence of a virus’s genetic material, whether DNA or RNA. This process allows researchers to read the virus’s entire genome, identify the virus, analyze its structure and function, detect mutations, and track genetic changes over time.

The key sequencing technologies of viral genome sequencing include next-generation sequencing, Sanger sequencing, and third-generation sequencing. Next-generation sequencing enables rapid, high-throughput analysis of viral genomes to detect mutations, track outbreaks, and support public health responses. Sample types include blood, nasal or throat swabs, saliva, and others. Applications include clinical diagnostics, research, epidemiology, vaccine development, and more, serving hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other end users.

Tariffs have affected the viral genome sequencing market by increasing the cost of importing high-end sequencing instruments, reagents, and software tools. Segments such as next-generation and third-generation sequencing technologies are most impacted, particularly in regions like North America and Europe that rely heavily on imports. While tariffs raise operational costs, they are encouraging local manufacturing, investment in domestic R&D, and the development of cost-effective sequencing solutions, creating opportunities for market diversification and innovation.

The viral genome sequencing market research report is one of a series of new reports that provides viral genome sequencing market statistics, including viral genome sequencing industry global market size, regional shares, competitors with a viral genome sequencing market share, detailed viral genome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the viral genome sequencing industry. This viral genome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.